Occupational Activity
Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy
Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.
Siemens Healthineers Expands U.S. Supply Chain with Strategic ‘Mega Depots’ to Combat Logistics Challenges
Siemens Healthineers, supply chain resilience, mega depots, logistics expansion, healthcare equipment, parts inventory, GXO partnership
Major Budget Cuts and Layoffs Hit US Health Agencies: Impacts on CDC, NIH, and Public Health
healthcare budget cuts, CDC layoffs, NIH funding reduction, public health impact, Trump administration, federal workforce reduction, medical research funding
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
Massive Layoffs Sweep Federal Health Agencies: Thousands of Workers Impacted Across HHS
HHS layoffs, federal health agencies, probationary workers, Trump administration, workforce reduction, CDC, NIH, FDA, CMS
Mass Layoffs at HHS: Trump Administration Cuts Thousands of Probationary Workers
HHS layoffs, probationary employees, Trump administration, CDC, NIH, FDA, federal workforce reduction, public health impact
Robert F. Kennedy Jr. Confirmed as HHS Secretary in Close Senate Vote
RFK Jr., HHS Secretary, Senate confirmation, Trump administration, vaccine skepticism, healthcare policy, Make America Healthy Again
Federal Judge Issues Nationwide Injunction on NIH Funding Cuts After Multi-State Lawsuit
NIH funding, research grants, federal judge, temporary restraining order, lawsuit, indirect costs, Trump administration
Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France
Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies
Eisai Anticipates Growth Acceleration for Alzheimer’s Drug Leqembi Despite Slow Initial Uptake
Leqembi, Alzheimer’s disease, Eisai, expansion phase, sales growth, diagnostics, maintenance dosing, patient adoption